medigraphic.com
Academia Mexicana de Neurología, A.C.

2005, Number 6

<< Back Next >>

Rev Mex Neuroci 2005; 6 (6)

Cerebral vasospasm. A challenge for the modern medicine

Varela HA, Vega BS, Herrera LO, De Zayas AE, Infante FJ

Language: Spanish
References: 42
Page: 491-499
PDF size: 67.04 Kb.


ABSTRACT

Objective: Many aspects related with cerebral vasospasm are even enigmatic and their management is complex. We carried out a revision of a group of representative articles of the main advances carried out in this field. Development: The literature revised show the advances achieved in the understanding of the endothelium molecular alterations seen in cerebral vasospasm, principally those related with nitric oxide and endothelins. It should always be kept in mind the risk factors for this frequent complication of the subarachnoid hemorrhage and their clinical manifestations for an opportune diagnosis by means of the current technologies like transcranial doppler and direct determinations of cerebral blood flow. Currently new therapeutic modalities such as transluminal angioplastie, nitric oxide donors and endothelins inhibitors are been applying. Conclusions: Cerebral vessels have a balanced autocrine and paracrine system whose alteration generates the physiopathologycal and clinical manifestations of cerebral vasospasm. The systematic application of the transcranial doppler to patients with subarachnoid hemorrhage and others complementary exams allow a more efficient application of the available therapeutic modalities. The development of new treatment techniques based on the basic investigations and on the clinical evidence will allow improving the presage of this entity.


REFERENCES

  1. Shaffrey ME, Shaffrey CI, Lanzino G, Kassell NF. Nonoperative treatment of aneurysmal subarachnoid hemorrhage. In: Youmans: Neurological Surgery. Philadelphia: Saunders; 1996; 1264-71.

  2. Heros CR, Marcos JJ. Cerebrovascular surgery: past, present and future. Neurosurg 2000; 47(5): 1007-33.

  3. Thomas JE. Molecular biological considerations in cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurosurg Focus 1997; 3: 1-5.

  4. Dietrich HH, Dacey GR. Molecular keys to the problems of cerebral vasospasm. Neurosurg 2000; 46(3): 517-30.

  5. Hansen-Schwartz J, Nordstrom HC, Edvinsson L. Human endothelin subtype A receptor enhancement during tissue cultura via de novo transcription. Neurosurg 2002; 50(1): 127-35.

  6. Moon TCh, Gajdusek C, London S, Mayberg RM. Expression of endothelial nitric oxide synthase after exposure to perivascular blood. Neurosurg 2001; 48(6): 1328-34.

  7. Ng HW, Moochhda S, Yeo TT, Ong LP, Ng YP. Nitric oxide and subarachnoid hemorrhage: elevated level of cerebrospinal fluid and their implications. Neurosurg 2001; 49(3): 622-27.

  8. Khaldi A, Zonner A, Reinert M, Woodward JJ, Bullock RM. Measurement of nitric oxide and brain tissue oxygen tension in patients after severe subarachnoid hemorrhage. Neurosurg 2001; 49(1): 33-40.

  9. Suzuki M, Kudo A, Otawara Y, Hirashima Y, Takaku A, Ogawa A. Extrinsic pathway of blood coagulation and thrombin in the cerebrospinal fluid after subarachnoid hemorrhage. Neurosurg 1999; 44: 487-94.

  10. Dunn TL, Stewart E, Murray DG, Nicoll ARJ, Teasdale MG. The influence of apolipoprotein E genotype on outcome after spontaneous subarachnoid hemorrhage: a preliminary study. Neurosurg 2001; 48(5): 1006-11.

  11. Sills AK, Catterbuck RE, Thompson RC, Cohen PL, Tamargo RJ. Endothelial cell expression of intercellular adhesion molecule 1 in experimental posthemorrhagic vasospasm. Neurosurgery 1997; 41(2): 453-61.

  12. Treggiari-Veuzi MM, Suter MP, Raund J. Review and medical prevention of vasospasm after subarachnoid hemorrhage: a problem of neurointensive care. Neurosurg 2001; 48(2): 249-62.

  13. Pareda-Cordentey AI, Falero-Pérez AR. Hemorragia subaracnoidea. Rev Neurol 2002; 34(10): 954-66.

  14. Okada Y, Shima T, Nishida M, Yamane K, Hatayama T, Yamanaka Ch, et al. Comparison of transcranial Doppler investigation of aneurismal vasospasm with digital subtraction angiographic and clinical findings. Neurosurg 1999; 45(3): 443-50.

  15. Vora YY, Suarez-Almazar M, Steinke ED, Martin ML, Findlay MJ. Role of transcranial Doppler monitoring in the diagnosis of cerebral vasospasm after subarachnoid hemorrhage. Neurosurg 1999; 44(6): 1237-48.

  16. Lam MKJ, Smielewski P, Czosnyka M, Pickard DJ, Kirkpatrick JP. Predicting delayed ischemic deficits after aneurismal subarachnoid hemorrhage using a transient hyperemic response test of cerebral autoregulation. Neurosurg 2000; 47(4): 819-26.

  17. Shimoda M, Takeuchi M, Tominaga J, Oda S, Kumasaka A, Tsugare R. Asymptomatic versus symptomatic infarcts from vasospasm in patients with subarachnoid hemorrhage: serial magnetic resonance imaging. Neurosurg 2001; 49(6): 1341-50.

  18. Otawara Y, Ogasawara K, Ogawa A, Sasaki M, Takahashi K. Evaluation of vasospasm after subarachnoid hemorrhage by use of multislice computed tomographic angiography. Neurosurg 2002; 51(4): 919-43.

  19. Quereshi IA, Sung YG, Suri KA, Straw NR, Guterman RL, Hopkins NL, et al. Prognostic value and determinants of ultraearly angiographic vasospasm after aneurismal subarachnoid hemorrhage. Neurosurg 1999; 44(5): 967-74.

  20. Rossenwasser HR, Armonda AR, Thomas EJ, Benítez PR, Gannon MP, Harrop J. Therapeutic modalities for the management of cerebral vasospasm. Neurosurg 1999; 44(5): 975-80.

  21. Takanashi Y, Ishida T, Meguro T, Kiwada H, Zhang HJ, Yamamoto I. Efficacy of intrathecal liposomal fasudil for experimental cerebral vasospasm alter subarachnoid hemorrhage. Neurosurg 2001; 48(4): 894-901.

  22. Laciñana-Cases M, Pérez-R EG, Díez-Tejedor E. Recomendaciones para el tratamiento y prevención del ictus. Rev Neurol 2004; 39(5): 465-86.

  23. Oskouian JR, Martin AN, Lee HJ, Glenn CTh, Guthrie D, Gonzalez RN, et al. Multimodal cuantitation of the effects of endovascular therapie for vasospasm on cerebral blood flow, transcranial Doppler ultrasonographic velocities, and cerebral artery diameters. Neurosurg 2002; 51(1): 30-43.

  24. Rosenwasser HR, Armonda AR, Thomas EJ, Benítez PR, Gannon MP, Harrop J. Therapeutic modalities for the management of cerebral vasospasm: timing of endovascular options. Neurosurg 1999; 44: 975-80.

  25. Pritz BM. Treatment of cerebral vasospasm due to aneurysmal subarachnoid hemorrhage: past, present and future of hyperdynamic therapy. Neurosurgery Quarterly 1997; 7(4): 273-85.

  26. Hoh LI, Carter SB, Ogilvy SCh. Risk of hemorrhage from unsecured, unruptured aneurysm during and after hypertensive hypervolemic therapy. Neurosurg 2002; 50(6): 1207-72.

  27. Hanjani AS, Schwartz BR, Sathi S, Stieg EP. Hypertensive encephalopathy as a complication of hyperdynamic therapy for vasospasm. Report of two cases. Neurosurg 1999; 44: 1113-16.

  28. Waterloo K, Sjoholm H, Solberg T, Ingebrigtsen T, Romner B. Prophylactic hyperdinamic postoperative fluid therapy after aneurismal subarachnoid hemorrhages: a clinical, prospective, randomized, controlled study. Neurosurg 2001: 49(3): 593-606.

  29. Boet R, Mee E. Magnesium sulfate in the management of patient with Fisher grade 3 subarachnoid hemorrhage: a pilot study. Neurosurg 2000; 47(3): 602-07.

  30. Kassell NF, Haley EC, Apperson-Hansen C, Stat M, Alves WM. Randomized, double-blind, vehicle- controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia and New Zeland. J Neurosurg 1996; 84: 221-28.

  31. Elsanesser SR, Zausinger S, Hungerhuber E, Baethmann A, Reulen JH. Neuroprotective effects of combination therapy with tirilazad and magnesium in rats subjected to reversible focal cerebral ischemia. Neurosurg 1999; 44: 163-72.

  32. Zimmermann M, Jung C, Raabe A, Spanehl O, Fach K, Seifert V. Inhibition of endotelio-converting enzyme activity in the rabbit basilar artery. Neurosurg 2001; 48(4): 902-10.

  33. Chow M, Dumont SA, Kassel FN. Endothelin receptor antagonists and cerebral vasospasm: an updated. Neurosurg 2002; 51(6): 1333-42.

  34. Aspey BS, Alp MS, Patel Y, Harrison MJ. Effects of combined glutamate and platelet-activating factor inhibition on the outcome of focal cerebral ischaemia: an initial screening study. Metab Brain Dis 1997; 12: 237-49.

  35. Luo Z, Harada T, London S, Gajdusek C, Mayberg MR. Antioxidant and Iron-chelating agents in cerebral vasospasm. Neurosurg 1995; 37(6): 1154-59.

  36. Arakawa Y, Kikuta K, Hojo M, Goto Y, Ishii A, Yamagata S. Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: Report of seven cases. Neurosurg 2001; 48(4): 723-30.

  37. Nakai K, Morimoto Y, Kikuchi M, Wada K, Shima K. Inhibition of experimental vasospasm by pretreatement with ultraviolet light irradiation in a rat femoral artery model. Neurosurg 2001; 48(6): 1318-27.

  38. Thomas JE, Nemirovsky A, Zelman V, Giannotta SL. Rapid reversal of endothelin-1-induced cerebral vasoconstriction by intrathecal administration of nitric oxide donors. Neurosurg 1997; 40: 1245-49.

  39. Thomas EJ, Rosenwasser HR. Reversal of severe cerebral vasospasm in three patients after aneurismal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans. Neurosurg 1999; 44(1): 48-58.

  40. Raabe A, Zimmerman M, Setter M, Vatter H, Berkefeld J, Seifert V. Effect of intraventricular sodium nitroprusside on cerebral hemodinamics and oxigenation in poor grade aneurysm patients with severe, medically refractory vasospasm. Neurosurg 2002; 50(5): 1006-14.

  41. Tierney ST, Clatterbuck ER, Lawson GH, Thai Q, Rhines DL, Tamargo JR. Prevention and reversal of experimental posthemorrhagic vasospasm by periadventitial administration of nitric oxide from a controlled-relased polymer. Neurosurg 2001; 49(4): 945-53.

  42. Weihl Ch, Macdonald L, Stoodley M, Luders J, Lin G. Gene therapy for cerebrovascular disease. Neurosurg 1999; 44(2): 239-53.




2020     |     www.medigraphic.com